Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles
Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.
1. A method for treating a mammal, including humans, suffering from a disease caused by and/or associated with an altered protein kinase activity, by administering to said mammal in need thereof a therapeutically effective amount of a bicyclo-pyrazole compound of formula (I):
wherein
R is an optionally further substituted group selected from the group consisting of —COR′, —COOR′, —CONHR′, —CONR′R″, —NH—C(═NH)NHR′, —C(═NH)NHR′, —SO 2 R′, —SO 2 NHR′ and —SO 2 NR′R″;
R 1 is a hydrogen atom or an optionally further substituted group selected from the group consisting of R′, —COR′, —COOR′, —CONHR′, —CONR′R″, —NH—C(═NH)NHR′, —C(═NH)NHR′, —SO 2 R′, —SO 2 NHR′ and —SO 2 NR′R″; wherein R′ and R″ are the same or different and are independently hydrogen, straight or branched C 1 -C 6 alkyl, aryl, C 3 -C 6 cycloalkyl or aryl C 1 -C 6 alkyl or R′ and R″ taken together form a C 4 -C 6 alkylene chain;
Ra, Rb, Rc and Rd, being the same or different, are independently selected among hydrogen, optionally further substituted straight or branched C 1 -C 6 alkyl, aryl, aryl C 1 -C 6 alkyl or —CH 2 OR′ groups, wherein R′ is as above defined, or Ra and Rb and/or Rc and Rd, taken together with the carbon atom to which they are bonded, form an optionally substituted C 3 -C 6 cycloalkyl group;
m and n, each independently, represents 0 or an integer from 1 to 2, provided that m+n is lower than, or equal to, 2 (m+n≦2);
or a pharmaceutically acceptable salt thereof, and wherein said disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of cancer and cell proliferative disorders wherein the cancer is selected from the group consisting of leukemia, ovary, colon, breast, lung, and pancreas.